GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Ending Cash Position

Bausch & Lomb (TSX:BLCO) Ending Cash Position : C$309 Mil (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Ending Cash Position?

Bausch & Lomb's Ending Cash Position for the quarter that ended in Mar. 2025 was C$309 Mil.

Bausch & Lomb's quarterly Ending Cash Position declined from Sep. 2024 (C$474 Mil) to Dec. 2024 (C$450 Mil) and declined from Dec. 2024 (C$450 Mil) to Mar. 2025 (C$309 Mil).

Bausch & Lomb's annual Ending Cash Position declined from Dec. 2022 (C$516 Mil) to Dec. 2023 (C$448 Mil) but then increased from Dec. 2023 (C$448 Mil) to Dec. 2024 (C$450 Mil).


Bausch & Lomb Ending Cash Position Historical Data

The historical data trend for Bausch & Lomb's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Ending Cash Position Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial 304.85 226.56 516.23 448.09 450.21

Bausch & Lomb Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 439.92 413.89 474.11 450.21 308.65

Bausch & Lomb Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Bausch & Lomb's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=475.849+-25.644
=450

Bausch & Lomb's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=453.65+-144.996
=309


Bausch & Lomb Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch & Lomb Business Description

Traded in Other Exchanges
Address
520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Executives
Ambrose Robert Douglas Bailey Senior Officer
Andrew Jude Stewart Senior Officer